VolitionRx Secures $2 Million Financing: What the Amended Deal Reveals About Future Prospects
Market Chameleon (Thu, 8-Jan 5:33 AM ET)
VolitionRx secures $2M financing through amended securities agreement; shares up
Seeking Alpha News (Thu, 8-Jan 9:43 AM ET)
VolitionRx Secures $2.0 Million in Funding
PRNewswire (Thu, 8-Jan 9:15 AM ET)
VolitionRx Announces Breakthrough Clinical Data for Nu.Q Vet Cancer Test in Cats
PRNewswire (Thu, 8-Jan 8:45 AM ET)
Market Chameleon (Wed, 17-Dec 4:55 AM ET)
Volition Issues Business Review 2025
PRNewswire (Wed, 17-Dec 8:45 AM ET)
PRNewswire (Thu, 11-Dec 9:00 AM ET)
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
PRNewswire (Mon, 8-Dec 9:00 AM ET)
PRNewswire (Thu, 4-Dec 9:00 AM ET)
PRNewswire (Tue, 25-Nov 8:45 AM ET)
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Volitionrx trades on the AMEX stock market under the symbol VNRX.
As of January 13, 2026, VNRX stock price declined to $0.32 with 84,301 million shares trading.
VNRX has a beta of 0.18, meaning it tends to be less sensitive to market movements. VNRX has a correlation of 0.00 to the broad based SPY ETF.
VNRX has a market cap of $39.30 million. This is considered a Sub-Micro Cap stock.
Last quarter Volitionrx reported $627,277 in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-1 million and met earnings estimates .
In the last 3 years, VNRX traded as high as $2.70 and as low as $.22.
The top ETF exchange traded funds that VNRX belongs to (by Net Assets): VXF.
VNRX has underperformed the market in the last year with a return of -50.9%, while the SPY ETF gained +20.7%. In the last 3 month period, VNRX fell short of the market, returning -31.0%, while SPY returned +6.5%. However, in the most recent 2 weeks VNRX has outperformed the stock market by returning +33.3%, while SPY returned +0.8%.
VNRX support price is $.32 and resistance is $.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VNRX shares will trade within this expected range on the day.
